Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · Real-Time Price · USD

9.85

-0.32 (-3.15%)

Apr 24, 2026, 4:00 PM EDT - Market closed

Immix Biopharma Earnings Call Transcripts

Fiscal Year 2025

Status Update

NXC-201 CAR T-cell therapy shows rapid, deep, and durable responses in relapsed/refractory AL amyloidosis, with a favorable safety profile and potential for outpatient use. If approved, it could address a major unmet need for over 20,000 U.S. patients.

Read full transcript →

Press Release

Powered by